- Recent Funding
- Investors
- Myelin VC
Myelin VC portfolio
Myelin VC has 1 portfolio company on record at Recent Funding.
About this page
It is a venture capital firm based in Montevideo. Its most recent investment on record is Wally Health's $3M Seed round in February 2023, alongside GFR Fund, Unfold.vc, Eudemian Ventures and 4 others. That company is in Health and bio.
About Myelin VC
What Myelin VC invests in
- Health and bio · 1 · 100%
- Consumer and social · 1 · 100%
How Myelin VC invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Seed | 1 100% | $3M |
Myelin VC portfolio companies
WWally Health$3MSeed · Feb 2023
| Company | Round with Myelin VC | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Seed · $3M | $28M | Oct 7, 2026 Series A |
Most frequent co-investors
UUnpopular Ventures1 shared round · last Feb 2, 2023
DDuro Ventures1 shared round · last Feb 2, 2023
BBling Capital1 shared round · last Feb 2, 2023
GGFR Fund1 shared round · last Feb 2, 2023
UUnfold.vc1 shared round · last Feb 2, 2023
EEudemian Ventures1 shared round · last Feb 2, 2023
JJack Abraham1 shared round · last Feb 2, 2023
Similar investors
AAllumia Ventures1 company · 1 deal in 12 mo
EEMERAM Capital Partners1 company · 1 deal in 12 mo
FFlipkart Ventures1 company · 1 deal in 12 mo
GGame Changers Ventures1 company · 1 deal in 12 moHHealthQuest Capital1 company · 1 deal in 12 mo
77 Gate Ventures1 company
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-09, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 1 round on Recent Funding that name Myelin VC. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Myelin VC, which is a subset of its real portfolio. API: /api/v1/investors/myelin-vc (get a free API key). More: the most active VC firms and new venture capital funds.